Safe Harbor

These presentations contain forward-looking statements (including, without limitation, information, and future guidance on the company's goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth opportunities, new products and solutions, customer service and innovation plans, financial condition and considerations, impact of acquisitions, share repurchases, dividends, the markets the company sells into, operations, manufacturing site plans and tax rates) that involve risks and uncertainties that could cause results of Agilent to differ materially from management's current expectations. The words “anticipate,” “plan,” “estimate,” “expect,” “intend,” “will,” “should,” “forecast,” “project” and similar expressions, as they relate to the company, are intended to identify forward-looking statements.

In addition, other risks that the company faces in running its operations include the ability to execute successfully through business cycles; the ability to successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross margin pressures; the risk that our strategic and cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties on our markets and our ability to conduct business; the impact of currency exchange rates on our financial results; the ability to improve asset performance to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix, the adverse impacts of and risks posed by the COVID-19 pandemic, and other risks detailed in the company's filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the fiscal year ended October 31, 2021.

The company assumes no obligation to update the information in these presentations. These presentations and the Q&A that follows include non-GAAP measures. Non-GAAP measures exclude primarily the impacts of asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, change in fair value of contingent consideration, loss on extinguishment of debt, business exit and divestiture costs, pension settlement loss and net gain on equity securities. We also exclude any tax benefits that are not directly related to ongoing operations and which are either isolated or are not expected to occur again with any regularity or predictability. With respect to the company’s guidance, most of these excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy. Accordingly, no reconciliation to GAAP amounts has been provided.
Agilent Results Q1’22

Scale and leading technology across Analytical Laboratories and Dx & Clinical markets

Q1’22 Financial Metrics

- **Revenues:** $1.67B, +8.9% y/y core(1)(2), +8.1% reported (-1.3% FX, 0.5% M&A).
- **Operating Margin:** 26.3%(2) of revenue, up 80 basis points y/y.
- **EPS:** $1.21(2), up 14% y/y.

Q1’22 Highlights

- **Growth** was driven by strength in Pharma and BioPharma, ongoing momentum in Chemical & Energy, and another excellent result in Dx & Clinical.
- **Margins:** driven by strong topline growth, improved pricing, and exceptional execution under challenging conditions from the OneAgilent team.
- **Capital Allocation:** Generated Operating Cash of $255M, invested $75M in capital expenditures, paid $63M in dividends, and repurchased 2.9M shares for $447M.

---

(1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.
(2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided.
(3) In Q1’22, Agilent implemented certain changes to its segment reporting structure. Historical segment information has been recast to reflect these changes.
• Q1 core revenue performance reflected strength in key end markets led by Pharma and Chemical & Energy. Momentum across all platforms led by Consumables, Spectroscopy, LC, and LC/MS.

• Announced plans to invest $20 million to expand our Shanghai manufacturing center to meet growing demand in China for advanced liquid chromatography (LC), spectrometer and mass spectroscopy (MS) systems.

• In February, acquired advanced artificial intelligence (AI) technology developed by Virtual Control, an AI and machine learning software developer that creates innovative analysis solutions in lab testing. This technology has the potential to significantly improve lab productivity and accuracy by automating manual interpretation of chromatography data.

• Q1’22 Revenue of $976M
• Y/Y Growth: +6% (+7% core\(^{(1)(2)}\))\(^{3}\)

(1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.
(2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided.
(3) In Q1’22, Agilent implemented certain changes to its segment reporting structure. Historical segment information has been recast to reflect these changes.
Agilent Cross Lab Group (ACG)

• ACG growth in Q1 was led by strong contract revenue across the portfolio, and demonstrated resiliency by delivering positive growth in every one of our regions and end markets.

• Q1’22 Operating Margin for the quarter was 25.2% (2), up 210 bps (3) versus last year.

• Q1’22 Revenue of $359M

• Y/Y Growth: +8% (+10% core (1)(2)(3))

(1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.
(2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided.
(3) In Q1’22, Agilent implemented certain changes to its segment reporting structure. Historical segment information has been recast to reflect these changes.
Diagnostics and Genomics Group (DGG)

- **Q1 core revenue growth** was led by another outstanding performance from NASD and strong double-digit growth in our genomics and cancer diagnostics businesses.

- Our Resolution Bioscience team achieved a major milestone in the first quarter and **completed pre-market approval submission for the Resolution CtDx FIRST liquid biopsy assay** as a companion diagnostic in conjunction with Mirati for non-small cell lung cancer and is currently under review by the FDA.

- **Q1’22 Operating Margin** was 20.1%(2), up 150 bps versus last year.

**Q1’22 Revenue of $339M**

- **Y/Y Growth:** +15% (+14% core(1)(2))

---

(1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.

(2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided.
Growth in a $63B+ Market – Q1’22 Results by End Market

Continued momentum in Pharma, C&E, and Dx & Clinical markets

Analytical Laboratory End Markets

- Q1’22 revenues: +9% y/y on core(2) basis
  - Pharma & Biotech: Up 17% on continued BioPharma strength in the US, Europe, and China
  - Chemical & Energy: Up 15% for a fourth consecutive quarter of double-digit growth, with strength in chemicals and advanced materials
  - Academia & Govt: Flat, as funding/shipping delays impact China and Omicron drives US colleges to return to remote learning in Jan
  - Environmental & Forensics: Down 11% as public investment in environmental testing has slowed while COVID drives other priorities
  - Food: Down 2% against a difficult Q1’21 compare of 22% growth. Funding for testing in China has slowed but elsewhere results are strong, with Cannabis driving US growth

Diagnostics and Clinical End Markets

- Q1’22 revenues: +11% y/y on core(2) basis
  - Diagnostics saw continued strength in Cancer Dx and Genomics. We are also seeing the expansion of LC/MS into this market driving a new vector of clinical growth

(1) % of Q1’22 Agilent revenue
(2) Core growth is reported growth adjusted for the effects of acquisitions and divestitures and FX.
Q2’22 and FY22 Guidance and Forward-looking Considerations
Based on January 31, 2022 Exchange Rates

<table>
<thead>
<tr>
<th>Q2’22 Guidance (1)</th>
<th>Low End</th>
<th>High End</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Revenue ($M)</td>
<td>$1,595</td>
<td>$1,625</td>
</tr>
<tr>
<td>Y/Y Core Revenue Growth (2)</td>
<td>6.5%</td>
<td>8.5%</td>
</tr>
<tr>
<td>Assumes -2.3% FX, +0.3% M&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS</td>
<td>$1.10</td>
<td>$1.12</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FY22 Guidance (1)</th>
<th>Low End</th>
<th>High End</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Revenue ($M)</td>
<td>$6,670</td>
<td>$6,730</td>
</tr>
<tr>
<td>Y/Y Core Revenue Growth (2)</td>
<td>7.0%</td>
<td>8.0%</td>
</tr>
<tr>
<td>Assumes -1.7% FX, +0.2% M&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS</td>
<td>$4.80</td>
<td>$4.90</td>
</tr>
</tbody>
</table>

**FY22 Financial Considerations**

- Net Interest + Other Income/Expense: ~$40M in net expense (~$10M in Q2)
- Non-GAAP Tax Rate at 14.25%
- Guidance assumes average diluted share count of 303M
- CapEx of $300M and Operating Cash Flow of $1.4-1.5B
- Shareholder Returns: $255M in dividends. Anti-dilutive share repurchases at a minimum
- $1.1B capacity remaining under current share repurchase authorization(3)

---

(2) Core growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.
(3) Per 10b5-1 plan, maximum of 2.6 M shares to be purchased on daily systematic basis.